European Leukemia Trial Registry
Trial: GMALL-MOLACT1-BLINA

More Details
Title Studie zum Einsatz des BiTE® Antikörpers Blinatumomab bei erwachsenen Patienten mit MRD-positiver B-Vorläufer ALL
Scientific Title A multicenter, single-arm study to assess the efficacy, safety, and tolerability of the BiTE® antibody blinatumomab in adult patients with minimal residual disease (MRD) of B-precursor acute lymphoblastic leukemia (Blast Successor Trial)
Short Title GMALL-MOLACT1-BLINA
Trialgroup GMALL
Type of Trial multicentric, single-group, prospective, open-label
Disease Acute lymphoblastic leukemia(ALL) B-Precursor ALL
Age >= 18 years
Status Active
Start of Recruitment 04.04.2017
Leader Gökbuget, Dr. med., Nicola
Centre of Trial Universitätsklinikum Frankfurt
Shortprotocol Shortprotocol
Diagnostics

MRD-Analysis
Hämatologie Labor Kiel

created 05.04.2017 Eva-Maria Ableidinger
changed 14.01.2020 Zenawit Krüger
© ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | www.leukemia-net.org | elic@leukemia-net.org